HRP20220176T1 - Konjugati hijaluronana s farmaceutski aktivnim tvarima, postupci i pripravci - Google Patents
Konjugati hijaluronana s farmaceutski aktivnim tvarima, postupci i pripravci Download PDFInfo
- Publication number
- HRP20220176T1 HRP20220176T1 HRP20220176TT HRP20220176T HRP20220176T1 HR P20220176 T1 HRP20220176 T1 HR P20220176T1 HR P20220176T T HRP20220176T T HR P20220176TT HR P20220176 T HRP20220176 T HR P20220176T HR P20220176 T1 HRP20220176 T1 HR P20220176T1
- Authority
- HR
- Croatia
- Prior art keywords
- hyaluronan
- conjugate according
- conjugate
- ester
- pharmaceutically active
- Prior art date
Links
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 title claims 29
- 229940099552 hyaluronan Drugs 0.000 title claims 29
- 229920002674 hyaluronan Polymers 0.000 title claims 29
- 238000000034 method Methods 0.000 title claims 6
- 239000013543 active substance Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical group ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 125000000600 disaccharide group Chemical group 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 125000005429 oxyalkyl group Chemical group 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229940014800 succinic anhydride Drugs 0.000 claims 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 150000003512 tertiary amines Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Claims (14)
1. Konjugat hijaluronana, naznačen time što sadrži hijaluronan koji ima slobodne poluesterske skupine i farmaceutski aktivni spoj vezan na hijaluronan preko poluesterskih skupina, gdje poluesterske skupine imaju duljinu lanca od 2-9 atoma.
2. Konjugat hijaluronana u skladu s patentnim zahtjevom 1, naznačen time što poluesterski lanac sadrži ugljičnu okosnicu, može sadržavati jedan ili dva atoma kisika u okosnici, te može sadržavati jedan ili više alkilnih, arilnih, oksialkilnih ili oksiarilnih ogranaka.
3. Konjugat hijaluronana u skladu s patentnim zahtjevom 1, naznačen time što su poluesterske skupine sukcinilni esteri.
4. Konjugat hijaluronana u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je hijaluronan umrežen.
5. Konjugat hijaluronana u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što se stupanj supstitucije kreće od 0,01 do 0,3 mol farmaceutski aktivnog spoja po molu disaharidne ponavljajuće jedinice hijaluronana.
6. Postupak dobivanja konjugata hijaluronana, naznačen time što se sastoji u osiguravanju hijaluronana u obliku otopine ili gela, reakciji hijaluronana u obliku otopine ili gela s anhidridnim reagensom kako bi se dobilo poluester hijaluronana s lancem duljine L između hijaluronana i esterske skupine, te zatim vezanja poluestera hijaluronana na farmaceutski aktivni spoj.
7. Postupak u skladu s patentnim zahtjevom 6, naznačen time što je duljina lanca L 2-9 atoma i sadrži ugljičnu okosnicu, može sadržavati jedan ili dva atoma kisika u okosnici.
8. Postupak u skladu s patentnim zahtjevom 6 ili 7, naznačen time što se hijaluronan nalazi u obliku otopine ili gela otapanjem hijaluronana u formamidu uz dodatak tercijarnog amina, te što je anhidridni reagens sukcinanhidrid.
9. Konjugat hijaluronana u skladu s bilo kojim od patentnih zahtjeva 1 do 5, ili postupak u skladu s patentnim zahtjevima 6 do 8, naznačeni time što poluesterske skupine imaju formulu:
-C(O)-CHRn-(CH2)(m-n)-COO-, gdje je n 0 ili 1, m = 2-8, a R = alkil, aril, O-alkil ili O-aril, ili
-C(O)-(CHRn)-(CH2)(p-1)-O-(CH2)q-COO-, gdje je n 0 ili 1, p i q su pojedinačno 1-4, a R = alkil, aril, O-alkil ili O-aril;
i po mogućnosti što poluesterske skupine imaju formulu:
-C(O)-(CH2)m-COO-, gdje je m 2-8,
-C(O)-(CH2)p-O-(CH)q-COO-, gdje su p i q pojedinačno 1-4, ili
-C(O)-(CH2)r-O-(CH)s-O-(CH2)t-COO-, gdje su r i t pojedinačno 1-2, a s je 2.
10. Konjugat hijaluronana u skladu s bilo kojim od patentnih zahtjeva 1 do 5 ili 9, ili postupak u skladu s bilo kojim od patentnih zahtjeva 6 do 9, naznačeni time što je farmaceutski aktivni spoj diklofenak ili deksametazon, te po mogućnosti što je farmaceutski aktivni spoj diklofenak.
11. Pripravak, naznačen time što sadrži konjugat hijaluronana u skladu s bilo kojim od patentnih zahtjeva 1 do 5, 9 ili 10,
12. Konjugat hijaluronana u skladu s bilo kojim od patentnih zahtjeva 1 do 5, 9 ili 10, ili pripravak koji sadrži konjugat hijaluronana u skladu s patentnim zahtjevom 11, naznačeni time što su namijenjeni upotrebi kao medikament.
13. Konjugat hijaluronana u skladu s patentnim zahtjevom 12, ili pripravak koji sadrži konjugat hijaluronana u skladu s patentnim zahtjevom 11, naznačeni time što su namijenjeni upotrebi kao medikament u liječenju bolesti zglobova, primjerice bolesti zglobova kod konja; namijenjeni upotrebi kao medikament u kirurškoj operaciji sive mrene; ili namijenjeni upotrebi kao medikament u terapiji raka.
14. Pripravak, naznačen time što sadrži konjugat hijaluronana u skladu s patentnim zahtjevom 11, naznačen time što je konjugat hijaluronana toplinski steriliziran i u puferiranoj fiziološkoj otopini, ili što pripravak sadrži hijaluronan molekulske težine od otprilike 100.000 do 4.000.000; ili što je konjugat hijaluronana u obliku gel matrice, suhog filma ili suhih čestica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461945491P | 2014-02-27 | 2014-02-27 | |
| EP15710918.2A EP3226905B1 (en) | 2014-02-27 | 2015-02-21 | Hyaluronan conjugates with pharmaceutically active substances, methods and compositions |
| PCT/IB2015/051331 WO2015128787A1 (en) | 2014-02-27 | 2015-02-21 | Hyaluronan conjugates with pharmaceutically active substances, methods and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220176T1 true HRP20220176T1 (hr) | 2022-04-29 |
Family
ID=52693002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220176TT HRP20220176T1 (hr) | 2014-02-27 | 2015-02-21 | Konjugati hijaluronana s farmaceutski aktivnim tvarima, postupci i pripravci |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10660906B2 (hr) |
| EP (2) | EP3226905B1 (hr) |
| CA (1) | CA2974611C (hr) |
| CY (1) | CY1125005T1 (hr) |
| DK (1) | DK3226905T3 (hr) |
| ES (1) | ES2905606T3 (hr) |
| HR (1) | HRP20220176T1 (hr) |
| HU (1) | HUE057871T2 (hr) |
| LT (1) | LT3226905T (hr) |
| PL (1) | PL3226905T3 (hr) |
| PT (1) | PT3226905T (hr) |
| RS (1) | RS62909B1 (hr) |
| SI (1) | SI3226905T1 (hr) |
| WO (1) | WO2015128787A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62909B1 (sr) | 2014-02-27 | 2022-03-31 | Synartro Ab | Konjugati hijalurona sa farmaceutski aktivnim supstancama, postupci i supstance |
| TWI706788B (zh) * | 2017-03-14 | 2020-10-11 | 日商生化學工業股份有限公司 | 關節疾患處置用組成物及含有該組成物的套組 |
| ES2964698T3 (es) | 2018-11-16 | 2024-04-09 | Seikagaku Kogyo Co Ltd | Composición farmacéutica |
| CN113750255B (zh) * | 2021-09-30 | 2023-10-31 | 大连民族大学 | 环境响应型透明质酸-鬼臼毒素前药胶束及其制备方法和应用 |
| WO2024038087A1 (en) | 2022-08-16 | 2024-02-22 | Synartro Ab | Method for preparing sterile compositions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE442820B (sv) | 1984-06-08 | 1986-02-03 | Pharmacia Ab | Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut |
| IT1281876B1 (it) | 1995-05-10 | 1998-03-03 | Fidia Advanced Biopolymers Srl | Acido ialuronico e suoi derivati esterei per la preparazione di matrici per il rilascio controllato di farmaci. |
| IT1281877B1 (it) | 1995-05-10 | 1998-03-03 | Fidia Advanced Biopolymers Srl | Sali di metalli pesanti di succinil derivati dell'acido ialuronico e loro impiego come potenziali agenti terapeutici |
| IT1294797B1 (it) * | 1997-07-28 | 1999-04-15 | Fidia Advanced Biopolymers Srl | Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante |
| EP1072070B1 (de) | 1997-12-31 | 2004-04-07 | Schleifring und Apparatebau GmbH | Anordnung zur übertragung elektrischer signale und/oder energie |
| CA2413002A1 (en) * | 2000-06-30 | 2002-12-19 | Banyu Pharmaceutical Co., Ltd. | Novel pyrazinone derivatives |
| US20030049253A1 (en) * | 2001-08-08 | 2003-03-13 | Li Frank Q. | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines |
| JP2004099581A (ja) * | 2002-09-09 | 2004-04-02 | Masashi Takahashi | 抗炎症剤 |
| WO2005066214A1 (ja) | 2004-01-07 | 2005-07-21 | Seikagaku Corporation | ヒアルロン酸誘導体及びそれを含む薬剤 |
| JP5043364B2 (ja) * | 2006-05-01 | 2012-10-10 | 生化学工業株式会社 | 多糖誘導体の製造方法 |
| IE20070900A1 (en) | 2007-12-12 | 2009-06-24 | Eurand Pharmaceuticals Ltd | New anticancer conjugates |
| EP2485767A1 (en) * | 2009-10-06 | 2012-08-15 | Ascendis Pharma A/S | Carrier linked paliperidone prodrugs |
| RU2014118642A (ru) * | 2011-10-12 | 2015-11-20 | Асцендис Фарма Офтальмолоджи Дивижн А/С | Предотвращение и лечение глазных нарушений |
| GB2510587B (en) * | 2013-02-07 | 2020-05-20 | Orthopaedic Res Uk | Biospecific agents for bone |
| RS62909B1 (sr) * | 2014-02-27 | 2022-03-31 | Synartro Ab | Konjugati hijalurona sa farmaceutski aktivnim supstancama, postupci i supstance |
-
2015
- 2015-02-21 RS RS20220144A patent/RS62909B1/sr unknown
- 2015-02-21 PT PT157109182T patent/PT3226905T/pt unknown
- 2015-02-21 CA CA2974611A patent/CA2974611C/en active Active
- 2015-02-21 SI SI201531786T patent/SI3226905T1/sl unknown
- 2015-02-21 US US15/121,675 patent/US10660906B2/en active Active
- 2015-02-21 PL PL15710918T patent/PL3226905T3/pl unknown
- 2015-02-21 DK DK15710918.2T patent/DK3226905T3/da active
- 2015-02-21 WO PCT/IB2015/051331 patent/WO2015128787A1/en active Application Filing
- 2015-02-21 EP EP15710918.2A patent/EP3226905B1/en active Active
- 2015-02-21 EP EP21214568.4A patent/EP3988121A1/en active Pending
- 2015-02-21 ES ES15710918T patent/ES2905606T3/es active Active
- 2015-02-21 HU HUE15710918A patent/HUE057871T2/hu unknown
- 2015-02-21 LT LTEPPCT/IB2015/051331T patent/LT3226905T/lt unknown
- 2015-02-21 HR HRP20220176TT patent/HRP20220176T1/hr unknown
-
2020
- 2020-04-16 US US16/850,253 patent/US11229656B2/en active Active
-
2021
- 2021-12-10 US US17/547,533 patent/US11642357B2/en active Active
-
2022
- 2022-02-22 CY CY20221100151T patent/CY1125005T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200237783A1 (en) | 2020-07-30 |
| CY1125005T1 (el) | 2023-01-05 |
| US20220168320A1 (en) | 2022-06-02 |
| CA2974611A1 (en) | 2015-09-03 |
| PL3226905T3 (pl) | 2022-04-19 |
| EP3226905B1 (en) | 2021-12-22 |
| US20160367684A1 (en) | 2016-12-22 |
| HUE057871T2 (hu) | 2022-06-28 |
| WO2015128787A1 (en) | 2015-09-03 |
| LT3226905T (lt) | 2022-03-10 |
| US11642357B2 (en) | 2023-05-09 |
| SI3226905T1 (sl) | 2022-04-29 |
| US11229656B2 (en) | 2022-01-25 |
| RS62909B1 (sr) | 2022-03-31 |
| EP3988121A1 (en) | 2022-04-27 |
| DK3226905T3 (da) | 2022-01-24 |
| ES2905606T3 (es) | 2022-04-11 |
| PT3226905T (pt) | 2022-01-19 |
| US10660906B2 (en) | 2020-05-26 |
| CA2974611C (en) | 2022-07-12 |
| EP3226905A1 (en) | 2017-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220176T1 (hr) | Konjugati hijaluronana s farmaceutski aktivnim tvarima, postupci i pripravci | |
| Raghuwanshi et al. | Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein | |
| CY1122129T1 (el) | Μεθοδοι για αγωγη πνευμονικων μη-φυματιωδων μυκοβακτηριακων λοιμωξεων | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2017518302A5 (hr) | ||
| Mishra et al. | Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer | |
| JP2014534220A5 (hr) | ||
| RU2016122957A (ru) | Способы применения интерлейкина-10 для лечения заболеваний и расстройств | |
| RU2008108516A (ru) | 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ | |
| RU2017112048A (ru) | Синергистические комбинации ауристана | |
| BR112015004501A2 (pt) | derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo | |
| CA2902372C (en) | Polymer conjugate for delivery of a bioactive agent | |
| RU2015133450A (ru) | Соединения имидазопиридина и их применение | |
| JP2012525393A5 (hr) | ||
| AR088458A1 (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod | |
| JP2008529745A5 (hr) | ||
| BR112019003479A2 (pt) | formulação e composição farmacêuticas, recipiente vedado, dispositivo de administração subcutânea, kit, forma de dosagem unitária farmacêutica, e, método para tratamento de um indivíduo sofrendo de uma doença ou de um distúrbio associados ao complemento dependente de masp-2. | |
| CY1118826T1 (el) | Διαδικασια για την κατασκευη ενος φαρμακευτικου σκευασματος που περιεχει glatiramer acetate | |
| BR112014016338A2 (pt) | polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos | |
| RU2018136872A (ru) | Композиции, содержащие 15-oh эпк, и способы их применения | |
| JP2016518464A5 (hr) | ||
| RU2017112303A (ru) | Способ применения комбинации нового производного гидроксамовой кислоты и антибактериального вещества | |
| HRP20180071T4 (hr) | Upotreba kladribina u liječenju očnog neuromijelitisa | |
| RU2017122809A (ru) | Фармацевтический состав полимерного производного, содержащего камптотецин | |
| MA53669A (fr) | Compositions et procédés d'administration d'acides nucléiques |